Navigation Links
New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Date:9/19/2007

HONOLULU, Sept. 19 /PRNewswire-FirstCall/ -- Results from a Phase III clinical trial evaluating the efficacy and safety of risedronate 150 mg once monthly for the treatment of postmenopausal osteoporosis were presented at the American Society for Bone and Mineral Research (ASBMR) 29th Annual Meeting. In the non-inferiority study comparing risedronate 150 mg once monthly to risedronate 5 mg daily [Actonel(R) (risedronate sodium tablets)] increases in bone mineral density (BMD) were similar for patients taking either the monthly or daily dosing regimens.

In the study, BMD was measured at the lumbar spine, total hip, femoral neck, and femoral trochanter. There were no statistically significant differences in BMD increases between the risedronate 150 mg once monthly and the 5 mg daily dose groups at 12 months. In the study, the tolerability and safety profiles were also similar for the monthly and daily dosing regimens of risedronate.

"Risedronate is already approved to reduce the risk of both spinal and nonspinal fractures," said Michael McClung, M.D., Founding Director of the Oregon Osteoporosis Center in Portland, Oregon. "For patients who prefer less frequent dosing, risedronate 150 mg, if approved, would provide the convenience of a once monthly dosing option."

About the Study

The MERIT-OP (Monthly Evaluation of Risedronate Trial in Osteoporosis) study is a 2-year, randomized, double-blind, active-control (5 mg daily risedronate) clinical trial which evaluated 1,292 postmenopausal women (94% Caucasian) between 50 and 88 years old, mean age 64.9, from 47 clinical centers in 13 countries. The participants had osteoporosis, defined as a lumbar spine (LS) BMD T-score less than -2.5 or a LS BMD T-score less than - 2.0 and at least one prevalent vertebral fracture. Patients were randomized to dosing regimens of either risedronate 150 mg monthly or risedronate 5 mg daily and received daily supplements of calcium (1,000 mg) and vitamin D (400
'/>"/>

SOURCE The Alliance for Better Bone Health
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...unt of research reflects depth and breadth of, co...p new treatments for divers... impact of Zometa(R), the leading IV, bisphosphona...reast cancer, - Four oral sessions to feature RAD...f mTOR, including first results of RECORD-1 study ...
(Date:5/15/2008)...TOULOUSE, France, May 15 /- Cerenis,T...eutical company,developing HDL-related compounds f...iseases, today announced that it has completed a P...any,s lead product candidates.,CER-002 is a peroxi...specific agonist in development for the treatment ...
(Date:5/15/2008)...Remains for an Antiplatelet Therapy that, Combined...ination of Plavix/Iscover and Aspirin, Accordi...AM, Mass., May 15 /- Decision Resourc...ry firms for pharmaceutical and,healthcare issues,...ers,improvement in patient compared to Sanofi-Aven...
(Date:5/15/2008)...15 /- Omega 3 fatty acids bound to,ph... credible natural,alternative and may have benefic... in vivo French study reveals. While several studi...hyperactivity, French researchers have,hypothesize...ffects on,impulse control., These research findin...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Ceramic heal thyself 2960 1Ceramic heal thyself 2960 2Accenx Technologies Announces New Leadership in Sales and Marketing Division 17219 1Accenx Technologies Announces New Leadership in Sales and Marketing Division 17219 221st Congress of the College of Neuropsychopharmacology 17215 121st Congress of the College of Neuropsychopharmacology 17215 2Computer Program Helps COPD Patients Monitor Breathing 17212 1Computer Program Helps COPD Patients Monitor Breathing 17212 2
... 2007 /PRNewswire-FirstCall/ -- Boston,Scientific ...rticle,in the Journal of of Cardiology (JACC) revi...tes the Company,s second-generation,TAXUS(R) Liber...icle in the April 24 edition of JACC concluded tha...e of the TAXUS Liberte Stent,system compared to th...
...--Jun 4, 2007 - Pfizer announced today that,axitin... inhibitor,of VEGFR 1, 2,3 (vascular endothelial g...itabine showed a trend towards prolonged,overall s...cancer,compared with gemcitabine alone, according...ial., These data were presented at the 43rd Americ...
Other Medicine Technology:Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 2Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 3Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 4New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 2New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 3New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 4
(Date:5/17/2008)...f a partial blockage last fall , , SATUR... Edward M. Kennedy was taken from a local hospital...assachusetts General Hospital in Boston early Satu...d possibly a second one, according to news reports... hospital, according to an early afternoon news re...
(Date:5/17/2008)...ather to tell motorists ,Click It or Ticket ...hoolers display art and videos promoting seat belt...t: Local kickoff of the 2008 "Click It or Ticket... Monday, May 19, 2008 Noon (free buffet l...here: The Cleveland House of Blues 308 E...
(Date:5/16/2008)...ire/ -- In the aftermath of central China,s,earthq... their lives, and,over 150,000 were injured. An es... 4 million who have lost their homes. With great s...upreme Master Ching Hai donated an,additional US$3...s from,Supreme Master Ching Hai International Asso...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
Breaking Medicine News(10 mins):Health News:Sen. Edward Kennedy Hospitalized After Seizure 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 3Health News:Supreme Master Ching Hai International Association Delivering US$160,000 in Aid to Earthquake Survivors in China 2
... at Stanford University School of Medicine and the...tes that more than 20 percent of low weight new- ...ould have been prevented. The babies would have s...fferent hospitals. Risky deliveries should be refe...
...The Journal of Strength and Conditioning Research ...experience a lowered response to resistance train...udy compared the response to a supervised upper ar...rogram in healthy, young adults who are overweight...
...cterium, Clostridium botulinum, produces the world...wipe off humanity from the face of the earth! Boto...is used medically. Now, the genome of the organis...esearch reveals that the bacterium does not posses...
...ults for the use of bronchial thermoplasty procedu...(RISA) Trial , at the annual scientific assembly ...mson,MD, Professor of Respiratory Medicine, Univer... from Asthmatx, Inc., a medical device company tha...
Other Medicine News:Health News:Low Weight Newborns at Greater Risk in Community Hospitals 2Health News:Low Weight Newborns at Greater Risk in Community Hospitals 3Health News:Genome of Botulism Bacterium Revealed 2Health News:Genome of Botulism Bacterium Revealed 3Health News:Bronchial Thermoplasty: Boon to Severe Asthma Patients? 2
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d
Made exclusively from LactoSorb Resorbable Copolymer.
The Stryker Cross-Screw System offers the surgeon a simple and secure method for ACL reconstruction utilizing soft tissue grafts. The Stryker Cross-Screw System provides the latest technology in femo
Medicine Products: